Zymeworks Inc. – Filings and Transcripts

NASDAQ: ZYME
Share price (9/24/26): $26.81
Market cap (9/24/26): $1.902 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Registration of securities for employees

Registration of securities for employees

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Schneider Paul R

Schneider Paul R

Rubric Capital Management LP

Perceptive Advisors LLC

News Filter

Completes Acquisition of Theravance Biopharma

U.S. FDA Approves Ziihera® (Zanidatamab-Hrii) With and Without Tislelizumab Plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

Provides Corporate Update and Reports Second Quarter 2026 Financial Results

To Acquire Theravance Biopharma, Inc

Announces Share Repurchase Program of Up to $125 Million of Its Common Stock

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness